PureTech announces receipt of FDA Fast Track Designation for LYT-200 in AML
PureTech Health (PRTC) announced that the U.S. Food and Drug Administration has granted Fast Track designation to LYT-200, a first-in-class anti-galectin-9 monoclonal antibody, for the treatment of acute myeloid leukemia.
PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML)
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that the U.
PureTech Drug Gets FDA Fast-Track Designation for Leukemia
The biotherapeutics company said the treatment, LYT-200, is being evaluated in two ongoing clinical trials. It was previously granted orphan drug designation for the treatment of acute myeloid leukemia, as well as a separate fast-track designation for the treatment of recurrent/metastatic head and neck squamous cell carcinomas.
A young man has been diagnosed with acute stage 3 leukemia and urgently needs help to survive. He has appealed to the general ...
Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...
Hosted on MSN2h
How Is Leukemia Diagnosed?Medically reviewed by Doru Paul, MD Leukemia is a cancer of the blood-forming tissues that often develops in the bone marrow.
HOUSTON, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize ® liposomal delivery and antisense technology to develop ...
A new study evaluating the quadratic phenotypic optimization platform shows it can accurately predict personalized drug ...
Researchers sought to determine if HRQoL measures differ with gilteritinib compared with placebo in patients with AML.
Amandeep Salhotra, MD, discussed the background and findings from a pilot trial evaluating enasidenib as post-hematopoietic ...
Two posters presented at the 2024 American Society of Hematology meeting reported real-world outcomes data for patients ...
In a significant advancement for cancer research, a team of scientists from Max Planck Institute for Biology Tübingen, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback